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Decline of a visceral leishmaniasis epidemic in HIV-infected
patients after the introduction of highly active antiretroviral
therapy (HAART)
Leishmania infantum causes endemic visceral leishmaniasis (VL)
in the Mediterranean basin. A progressive increase in the
number of cases of VL has been observed in southern Europe
since the mid-1980s. VL is considered an emerging opportu-
nistic disease, mainly due to the HIV pandemic: between 25 and
75% of cases of adult VL occur in HIV-positive patients and
2–9% of AIDS patients suffered VL [1,2]. These figures were
obtained at a time when doctors had only a handful of weak
drugs to treat HIV infection. Since the introduction of protease
inhibitor (PI)-containing regimens, an increase in survival rates
and a decline in the number of HIV-associated opportunistic
infections have been observed [3]. However, very few data are
available concerning the effect of PI on Leishmania–HIV co-
infected patients.
The objective of this study was to determine if the introduc-
tion of highly active antiretroviral therapy (HAART) with PI-
containing regimens was able to reduce the number of new VL
cases in HIV-infected patients. The study was performed at the
Ramo´n y Cajal Hospital (Madrid, Spain), a public hospital with
1100 beds, serving a well defined area in northern Madrid
(officially called Area 4). This hospital is the only source of
tertiary level care for the 550 000 population living in that area.
From 1987 to 1999, HIV-infected patients diagnosed with a
first episode of VL were recorded. Most HIV-infected patients
were evaluated every 3 months, or more frequently if necessary.
An active search for Leishmania was conducted in all patients
with prolonged fever and/or visceromegalies and/or cyto-
penias. Diagnosis of VL was accepted only if (i) there was a
compatible clinical illness; (ii) there was parasitologic confirma-
tion by demonstration of Leishmania amastigotes in Giemsa-
stained smears; (iii) promastigotes were isolated in parasitic
culture (NNN medium) obtained from aspirates of spleen,
lymph node, blood, liver or bone marrow. No search for the
parasite was carried out in asymptomatic patients. CD4þ count
was measured by flow cytometry. HIV RNA levels were
determined by an ultrasensitive method with a lower limit of
detection of 50 copies/mL (Chiron Diagnostics, Emeryville,
CA, USA). During follow-up, antiretroviral treatment change
was decided by the clinician caring for the patient, according
to published guidelines.
Pre-HAART era: From 1987 to 1996 (a 120-month study
period), a total of 72 newly diagnosed cases of VL were
recorded. At the time of their first episode of VL, 42.3%
patients met the European diagnostic criteria for AIDS, but
most patients were strongly immunocompromised (mean
CD4þ¼ 47 cells/mL). Clinico-epidemiological characteristics,
survival and prognostic factors of those patients have been
published previously [4].
HAARTera: PI was started on some patients in 1996, but the
majority of HIV-infected patients received PI from January
1997, the point at which the second phase of the study
was started, until December 1999 (36 months). A first episode
of VL after starting HAART (average time 22 months, range
6–26) was recorded in three patients. All of these patients
were non-responders (failure of the antiretroviral drugs).
When VL was diagnosed, they had an average CD4þ count
of 82 cells/mm3 (range 30–144) and viral load of 5.9 log (range
5.8–6 log).
There was a decrease in the incidence of new VL cases during
HAART (3/375; 0.8 new VL cases per 100 AIDS cases; i.e. 0.26
new VL cases per 100 AIDS person/years) compared with the
pre-HAART era (72/1479; 4.81 new VL cases per 100 AIDS
cases, i.e. 0.48 new VL cases per 100 AIDS person/years) was
observed (P< 0.0005). The occurrence of new VL cases before
and after HAART is shown in Table 1.
The benefit of HAART in reducing the incidence of nearly
all AIDS-defining opportunistic infections is well known, but
very few data are presently available on the effect of HAART
on leishmaniasis. The results obtained point out a significant
decrease in the incidence of new VL cases in HIV-infected
patients after the introduction of HAART. These results are in
accordance with other studies carried out in Rome, Italy (a
decrease from 0.7 cases per 100 person/years to 0.13 cases per
100 person/years) [5], in Barcelona, Spain (a decrease from 0.8
cases per 100 person/years to 0.12 cases per 100 person/years)
[6], and in Seville, Spain (a decrease from 1.9 cases per 100
persons/2 years to 0.3 cases per 100 persons/2 years) [7]. No
controls were included in any of these studies and the decrease
of VL–HIV cases could be coincidental, as Leishmania could be
transmitted by sharing syringes among intravenous drug users.
A decrease in new VL cases could be attributed to the intro-
duction of syringe exchange programs or other alternative
hypotheses besides the antiretroviral treatment.
On the other hand, it is not yet clear if HAART is able to
reduce VL recurrence in HIV-infected patients with a previous
VL episode. Some studies have found little, if any, benefit to
receiving HAART, even if an undetectable viral load and
marked CD4þ increase above 200 cells/mL was achieved,
and prevented a relapse in the VL–HIV co-infected [8,9].
VL is controlled by cellular immunity, and TH1 response
results in host protective immunity to Leishmania. HIV and
Leishmania multiply their effects if they occur concurrently,
switching from TH1 to TH2 CD4þ response. HAART could
be strong enough to inhibit viral replication but not to switch
from TH2 to TH1 response in some patients. In addition to this,
other factors (such as parasite virulence, parasitic load, indivi-
dual susceptibility, host parasitic immunity before HIV infec-
tion) may play a role in explaining the differences in the host
immune response and clinical evolution observed among
patients [10].
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Although the number of patients in our study is small, the
results indicate that HAART decreases the incidence of new
cases of VL and that this opportunistic parasitic disease appears
only when there is evidence of HAART failure. In our study,
the only three new cases of VL after 1997 were non-responders
to HAART therapy.
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Table 1 Occurrence of new cases of visceral leishmaniasis before and after starting highly active antiretroviral therapy (HAART) including protease inhibitor-
containing regimens
Pre-HAARTera HAARTera P-value
Interval 1987^96 1997^99
(120months) (36months)
HIV therapy NRTIs HAART
AIDS new cases 1497 375
VL-new cases 72 3
VL-new cases per100 AIDS cases 4.81
(95% CI=3.84^6.01)
0.80
(95% CI=0.27^2.33)
<0.0005
NRTIs, nucleoside reverse-transcriptase inhibitors; HAART, highly active antiretroviral therapy with protease inhibitor-containing regimens; VL, visceral leish-
maniasis; AIDS, acquired immunodeficiency syndrome; 95% CI,95% confidence interval.
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